Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

IGFBP-3 sensitizes antiestrogen-resistant breast cancer cells through interaction with GRP78.

Li C, Harada A, Oh Y.

Cancer Lett. 2012 Dec 28;325(2):200-6. doi: 10.1016/j.canlet.2012.07.004. Epub 2012 Jul 16.

PMID:
22801219
2.

Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.

Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID.

J Cell Biochem. 2008 Feb 1;103(2):624-35.

PMID:
17562544
3.

Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.

Leveque J, Foucher F, Havouis R, Desury D, Grall JY, Moulinoux JP.

Anticancer Res. 2000 Jan-Feb;20(1A):97-101.

PMID:
10769640
4.

Antiestrogens are pro-apoptotic in normal human breast epithelial cells.

Somaï S, Chaouat M, Jacob D, Perrot JY, Rostène W, Forgez P, Gompel A.

Int J Cancer. 2003 Jul 10;105(5):607-12.

5.

BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.

Brinkman A, van der Flier S, Kok EM, Dorssers LC.

J Natl Cancer Inst. 2000 Jan 19;92(2):112-20.

PMID:
10639512
7.

EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.

Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS.

Cancer Res. 2003 Jun 15;63(12):3425-9.

8.

Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line.

Parisot JP, Leeding KS, Hu XF, DeLuise M, Zalcberg JR, Bach LA.

Breast Cancer Res Treat. 1999 Jun;55(3):231-42.

PMID:
10517168
9.

Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.

Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R.

Oncogene. 2002 Nov 21;21(53):8158-65.

10.

MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.

Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R.

Cancer Res. 1997 Aug 15;57(16):3486-93.

11.

mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.

Revillion F, Pawlowski V, Lhotellier V, Louchez MM, Peyrat JP.

Anticancer Res. 2003 Mar-Apr;23(2B):1455-60.

PMID:
12820409
12.

Cyr61 promotes breast tumorigenesis and cancer progression.

Tsai MS, Bogart DF, Castañeda JM, Li P, Lupu R.

Oncogene. 2002 Nov 21;21(53):8178-85.

13.

A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.

Kurebayashi J, Otsuki T, Yamamoto S, Kurosumi M, Nakata T, Akinaga S, Sonoo H.

Oncology. 1998 Dec;55 Suppl 1:23-34.

PMID:
9852399
14.

Expression and regulation of Cyr61 in human breast cancer cell lines.

Tsai MS, Bogart DF, Li P, Mehmi I, Lupu R.

Oncogene. 2002 Jan 31;21(6):964-73.

15.

Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.

Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U, Jepsen JS.

Growth Horm IGF Res. 2006 Aug;16(4):224-39. Epub 2006 Aug 8.

PMID:
16893667
17.

Breast cancer-derived M543V mutation in helix 12 of estrogen receptor alpha inverts response to estrogen and SERMs.

Nichols M, Cheng P, Liu Y, Kanterewicz B, Hershberger PA, McCarty KS Jr.

Breast Cancer Res Treat. 2010 Apr;120(3):761-8. doi: 10.1007/s10549-009-0437-7. Epub 2009 Jun 13.

PMID:
19526339
18.

Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.

Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Künzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G, Gieschen H, Ulbrich HF, Schneider MR.

J Natl Cancer Inst. 2004 Feb 4;96(3):210-8.

PMID:
14759988
20.

Supplemental Content

Support Center